Status:
COMPLETED
Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults
Lead Sponsor:
CV Technologies
Collaborating Sponsors:
Capital Health, Canada
Conditions:
Upper Respiratory Infection
Eligibility:
All Genders
18-64 years
Phase:
PHASE3
Brief Summary
The purpose of the Study is to determine the prophylactic effects of CVT-E002 treatment for upper respiratory tract infections in healthy adult employees working with residents in continuing care faci...
Detailed Description
Eligible continuing care employees will be randomly assigned to either the treatment or placebo group with equal numbers in each group. The treatment will consist of taking two capsules of CVT-E002 (4...
Eligibility Criteria
Inclusion
- age 18-64 years
- not pregnant or breast feeding
- good general health
Exclusion
- medical conditions: HIV infection; malignancy; cardiovascular disease; hypertension; renal, pulmonary or hepatic abnormalities; neurologic or psychiatric disease; tuberculosis; multiple sclerosis; recent acute respiratory infection (\<2 weeks)
- medications: warfarin; immunosuppressive therapy; corticosteroids; phenalzine; pentobarbital; haloperidol
- major surgical procedure in the previous six months
- history of alcohol/drug abuse
- pregnancy and lactation in women
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00259831
Start Date
December 1 2005
End Date
August 1 2006
Last Update
June 8 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Capital Care Group Continuing Care facilities
Edmonton, Alberta, Canada, T5K 2J8